HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

63_EJ15-0749.pdf917.16 kBPDF見る/開く

タイトル: Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy
著者: Yamamoto, Chiho 著作を一覧する
Miyoshi, Hideaki 著作を一覧する
Ono, Kota 著作を一覧する
Sugawara, Hajime 著作を一覧する
Kameda, Reina 著作を一覧する
Ichiyama, Mei 著作を一覧する
Yamamoto, Kohei 著作を一覧する
Nomoto, Hiroshi 著作を一覧する
Nakamura, Akinobu 著作を一覧する
Atsumi, Tatsuya 著作を一覧する
キーワード: Diet therapy
Visceral adipose tissue
発行日: 2016年 6月
出版者: The Japan Endocrine Society
誌名: Endocrine Journal
巻: 63
号: 6
開始ページ: 589
終了ページ: 596
出版社 DOI: 10.1507/endocrj.EJ15-0749
抄録: To investigate if ipragliflozin, a novel sodium-glucose co-transporter 2 inhibitor, alters body composition and to identify variables associated with reductions in visceral adipose tissue in Japanese patients with type 2 diabetes mellitus. This prospective observational study enrolled Japanese participants with type 2 diabetes mellitus. Subjects were administered ipragliflozin (50 mg/day) once daily for 16 weeks. Body composition, visceral adipose tissue volume and plasma variables were measured at 0, 8, and 16-weeks. The subjects' lifestyle habits including diet and exercise were evaluated at baseline and 16 weeks. The primary endpoint was defined as the decrease of visceral adipose tissue mass. Twenty-four of 26 enrolled participants completed the study. The visceral adipose tissue decreased significantly (110 ± 33 to 101 ± 36 cm2, p = 0.005) as well as other parameters for metabolic insufficiency including hemoglobin A1c. Seventy-one % of the total body weight reduction (-2.49 kg) was estimated by a decrease in fat mass (-1.77 kg), and the remaining reduction (22%) by water volume (-0.55 kg). A minor but significant reduction in the skeletal muscle index was also observed. Correlation analyses were performed to identify variables associated with changes in visceral adipose tissue and the only significant variable identified was diet therapy (Spearman's r = -0.416, p = 0.043). Ipragliflozin significantly decreased visceral adipose tissue, and improved parametres for metabolic dysfunction. Adequate diet therapy would be necessary to induce and enhance the therapeutic merit.
資料タイプ: article
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学